The HPV vaccination programme, launched recently, aims to drastically reduce the incidence of cervical cancer in the country. With the Human Papillomavirus (HPV) identified as the leading cause of this type of cancer, the initiative is crucial for public health. The World Health Organization recommends the HPV vaccine for girls aged 9–14 years, aligning with India’s focus on vaccinating adolescent girls to curb future cases of cervical cancer.

In a promising start, India’s HPV vaccination campaign has already vaccinated nearly 3 lakh girls aged 14 within just two weeks of its launch. This rapid uptake highlights the community’s response to the health initiative and the potential for significant impact on public health outcomes. The vaccines, including Gardasil® and the indigenous Cervavac®, are designed to protect against various strains of HPV, including those most commonly associated with cervical cancer.

Gardasil® is known for its efficacy in preventing HPV infection and subsequent cervical cancer, while Cervavac®, which received approval from the Drug Controller General of India in July 2022, represents a significant advancement in local vaccine development. The introduction of Cervavac® is particularly noteworthy as it adds to the options available for vaccination, potentially increasing coverage and accessibility.

Dr (Brig.) Rakesh Gupta emphasized the importance of accessibility in vaccination efforts, stating, “The idea is to create a dedicated space where vaccination services are available throughout the week without disruption.” This approach aims to ensure that girls can receive their vaccinations conveniently, thereby enhancing participation in the program.

HPV vaccines were first introduced in India in 2008, with state governments launching various programs in 2016. The current initiative builds on this foundation, aiming to improve public health infrastructure and raise awareness about the importance of vaccination in preventing cervical cancer. A single dose of the HPV vaccine has been shown to provide durable immunity for up to 18 years, making it a long-term solution for HPV-related health issues.

Looking ahead, the Indian government, in collaboration with organizations like Gavi and the World Health Organization, is expected to continue its efforts to expand the HPV vaccination program. The policy highlights for cervical cancer vaccination drives are set for 2024–25, indicating a long-term commitment to combating this preventable disease.

As the vaccination campaign progresses, it is crucial to monitor its impact on cervical cancer rates in the coming years. The initial success in vaccinating a significant number of girls is a positive sign, but sustained efforts will be necessary to achieve the program’s goals and ensure that the burden of cervical cancer is significantly reduced in India.

The post HPV Vaccination Program Aims to Reduce Cervical Cancer in India appeared first on newscri.